Internation Circulation: Professor Zhang, you’ll be talking about the FEVER trial.Regarding treatment targets,sometimes when we are pursuing just a number such as a target blood pressure or with patients with both hypertension and diabetes a target blood glucose, have we ignored the fact that treating the patient as a whole, paying attention to their entire condition? If we are assessing patients for total CV risk stratification, is there a way to assess this in more of an overall fashion? 《国际循环》:张教授,您将谈及FEVER试验。就治疗目标而言,有时当我们追求的仅仅是一个数值,如高血压患者的目标血压值或合并糖尿病患者的目标血糖值,是不是我们忽略了要将患者作为一个整体来治疗的事实以及应注意他们的整体状况? 如果我们评估患者来进行总体CV危险分层,那么对于治疗目标是否有更为整体的评估方法?
Zhang Yuting: It is important to calculate the patient’s risk, perhaps a 10-year risk, with the baseline characteristics of their blood pressure level. Of course according to the current European Society’s guidelines we are encouraged to use more measurements will be more helpful in assessing the total risk.Currently in China we encourage doctors to use more devices and measurements in order to calculate risk. 张宇清教授:根据患者血压水平和基线特征来计算患者的风险(可能是10年风险)很重要。当然,根据目前欧洲协会的指南,我们被鼓励采用更多的检测,这在评估总体风险中会更有帮助。当前,在中国,我们鼓励医生应用更多的设备和检测来计算风险。
上一页 [1] [2] [3] [4] 下一页
网友评论仅供其表达个人看法,并不表明国际循环同意其观点或证实其描述。 发表评论需登陆